Home

Aaron Royston

CIK 1727703 · last filed 2026-07-29

Aaron Royston is a corporate insider who has filed 7 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for ACHV, was dated Jul 29, 2026. Across all open-market trades the lifetime net is +$9.0M, making them a net buyer over the disclosed history. 3 SEC filings were submitted jointly with Robert J Adelman.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

7

Lifetime Open-Market Net

$9.00M

Filer Profile

Reported Address
200 CARDINAL WAY, 2ND FLOOR
REDWOOD CITY, CA 94063
Related Filers
Robert J Adelman — 3 joint filings, latest 2022-05-27
COREY S GOODMAN — 3 joint filings, latest 2022-05-27
venBio Global Strategic Fund III, L.P. — 3 joint filings, latest 2022-05-27
Attovia Therapeutics, Inc. — 1 joint filings, latest 2026-08-04
VENBIO GLOBAL STRATEGIC GP III, LTD — 1 joint filings, latest 2021-06-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACHV Director — $7.06 — $0 1 2026-07-29
Ventyx Biosciences, Inc. (VTYX) Delisted Director 3,684,769 $13.99 $51.55M $5.00M 3 2023-04-26
VYNE Therapeutics Inc. (MNLO) Delisted Director — — — $0 2 2019-08-08
Akero Therapeutics, Inc. (AKRO) Delisted Director 3,954,858 $54.65 $216.13M $4.00M 1 2019-06-25

Recent Filings

7 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-29 ACHV Grant (A) — $0 EDGAR
2023-04-26 Ventyx Biosciences, Inc. (VTYX) Delisted Grant (A) — $0 EDGAR
2022-06-10 Ventyx Biosciences, Inc. (VTYX) Delisted Grant (A) — $0 EDGAR
2021-10-25 Ventyx Biosciences, Inc. (VTYX) Delisted Mixed +3,997,269 $5.00M EDGAR
2019-08-08 VYNE Therapeutics Inc. (MNLO) Delisted Grant (A) — $0 EDGAR
2019-06-27 VYNE Therapeutics Inc. (MNLO) Delisted Grant (A) — $0 EDGAR
2019-06-25 Akero Therapeutics, Inc. (AKRO) Delisted Mixed +3,954,858 $4.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.